Germany’s Vaccine Industry In Danger Of Disappearing, Says GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.
You may also be interested in...
Making The Case For Vaccines In Europe: A Conversation With Sanofi’s Andrea Rappagliosi
Sanofi Pasteur MSD’s Andrea Rappagliosi also is president of Vaccines Europe, an industry group that just launched an initiative to promote the preventive health value of vaccines.
German Vaccine Reforms Offer Multiple Tenders; Firms Want Purchase Guarantees
Government argues that shortages can be avoided by contracting with multiple manufacturers, but industry says changes do not go far enough, and is asking for sales assurances.
Novartis Flu Vaccine Nightmare Ends; Worries Over Pharmacovigilance Overreaction Remain
As Italy, France, Switzerland and Austria lift bans on two Novartis flu vaccines, Germany’s more sober approach to specific batch suspensions proves more palatable for manufacturers.